Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $32.67 Consensus Target Price from Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been assigned a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $32.67.

AMLX has been the topic of a number of research analyst reports. Evercore ISI reiterated an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Mizuho lowered shares of Amylyx Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, March 8th. Robert W. Baird lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research report on Monday, March 11th. Finally, Leerink Partnrs lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th.

Insider Activity

In related news, CEO Joshua B. Cohen sold 4,135 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total value of $77,448.55. Following the completion of the transaction, the chief executive officer now owns 3,023,002 shares in the company, valued at approximately $56,620,827.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Gina Mazzariello sold 2,838 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $18.76, for a total transaction of $53,240.88. Following the transaction, the insider now owns 46,245 shares in the company, valued at approximately $867,556.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joshua B. Cohen sold 4,135 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $77,448.55. Following the transaction, the chief executive officer now owns 3,023,002 shares in the company, valued at approximately $56,620,827.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,305 shares of company stock worth $193,098. Corporate insiders own 11.80% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Premier Path Wealth Partners LLC purchased a new position in Amylyx Pharmaceuticals during the fourth quarter valued at $298,000. Graham Capital Management L.P. increased its holdings in shares of Amylyx Pharmaceuticals by 84.1% during the third quarter. Graham Capital Management L.P. now owns 56,241 shares of the company’s stock valued at $1,030,000 after acquiring an additional 25,689 shares in the last quarter. Rafferty Asset Management LLC bought a new position in shares of Amylyx Pharmaceuticals during the third quarter valued at $207,000. Qube Research & Technologies Ltd increased its holdings in shares of Amylyx Pharmaceuticals by 31.0% during the third quarter. Qube Research & Technologies Ltd now owns 162,710 shares of the company’s stock valued at $2,979,000 after acquiring an additional 38,530 shares in the last quarter. Finally, Primecap Management Co. CA bought a new position in shares of Amylyx Pharmaceuticals during the third quarter valued at $5,583,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $2.00 on Monday. The firm has a 50 day simple moving average of $8.83 and a 200-day simple moving average of $13.09. The stock has a market capitalization of $135.56 million, a PE ratio of 2.86 and a beta of -0.93. Amylyx Pharmaceuticals has a 12-month low of $1.98 and a 12-month high of $31.77.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. Amylyx Pharmaceuticals had a net margin of 12.94% and a return on equity of 12.39%. The firm had revenue of $108.45 million during the quarter, compared to analyst estimates of $106.40 million. During the same quarter last year, the business posted ($0.65) EPS. On average, analysts forecast that Amylyx Pharmaceuticals will post -1.01 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.